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ABSTRACT 
 
Carbapenem resistant organisms (CROs) have emerged as a public health crisis because 
of high rates of mortality and morbidity. Epidemiologic and clinical factors contributing to 
patient outcomes vary. Objectives included evaluating emergence of CROs, and identifying 
factors associated with patient mortality at UPMC Presbyterian hospital.  Microbiology records 
were extracted from the most common gram-negative pathogens, E.coli(Ecol), Klebsiella 
pneumoniae(Klpn), Pseudomonas aeruginosa(Psar), Enterobacter aerogenes/cloacae(Entb), 
Serratia marcescens(Serm), and Acinetobacter baumannii(Acat) from 2000-2015. 
We identified 84,597 isolates from 37,823 patients. Among all isolates 9.5% (8,864) were 
classified as CROs. Standardized by patient, 7.5% of isolates were CR in 2000, 14.6% in 2015 
(P<0.001). Among all CROs Psar-58%, Klpn-17%, Acat-12%, Ent-7%, Ecol-4%, and Serm-2%. 
Psar accounted for 86% of CROs in 2000 but only 55% in 2015 (P<0.0001). Conversely, Acat, 
Klpn, and Ent increased from 1-4% CR isolates, to 9%, 19%, and 15%, respectively (P<0.0001 
for each). Psar was the most common CR pathogen annually. Various CROs emerged as second 
most common (Acat, 2010; Klpn, 2012; Ent, 2014). Recurrence rates at 90-days were highest for 
Psar(23%), and lowest for Ecol(3%, P<0.001). Carbapenem daily defined doses (DDD’s)/1,000 
patient days increased over the study (P<0.001); other antibiotic doses did not change. By cross-
correlation analysis, carbapenem DDDs correlated with emergence of CROs at zero-lag time 
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interval (R2=0.90, P<0.001), indicating that increased consumption and emergence of CROs 
occurred simultaneously.  
CROs were identified from 4,994 patients; mean age was 57.8 years, 56% were men, 
41% were ICU residents, and 26% were solid-organ-transplant(SOT) recipients. Mortality rates 
at 30-d and 90-d were 19% and 32%, respectively. Rates at 30-d were higher for Acat(28%, 
P<0.001), lower for Psar(17%, P<0.001). Rates ranged by culture site from 27% (blood) to 12% 
(urine, P<0.001). Age (OR=1.02, 95% CI:1.016-1.026, P<0.001) and ICU residence (OR=3.63, 
95% CI:3.10-4.26, P<0.001) were independent predictors of 30d mortality. SOT recipients had 
lower mortality rates(P<0.001). A prediction model was constructed to estimate 30d mortality 
risk. CROs emerged in waves at our center, but were not associated with increased carbapenem 
usage. CROs are associated with high mortality rates. Prediction models may be useful for 
clinician evaluation and reduction of this public health burden.   
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1.0  INTRODUCTION 
Antimicrobial resistance has emerged as a healthcare crisis around the world. The World 
Health Organization (WHO) defines antimicrobial resistance (AMR) as the ability of a 
microorganism, like bacteria, to prevent an antimicrobial, such as antibiotics, from working against 
it (WHO, 2016). When bacteria develop non-susceptibility to at least one agent within three or 
more categories of antimicrobials, they are classified as Multidrug-Resistant Organisms (MDROs) 
(Magiorakos et al., 2012).  
The rising prevalence of MDROs is an increasing public health threat according to the 
Centers for Disease and Control (CDC, 2009a). Increasing rates of MDROs are a result of 
excessive and inappropriate antimicrobial use (Chaisathaphol & Chayakulkeeree, 2014), (Tuon, 
Gortz, & Rocha, 2012), (Tun et al., 2016), (Brotfain et al., 2016).  Carbapenems are a class of 
antibiotics that exhibit a broad antimicrobial spectrum and stability against common antimicrobial 
resistance mechanisms. Accordingly, carbapenems have been increasingly utilized for the 
treatment of MDROs. As one of the last lines of defense, bacterial resistance to the carbapenems 
presents a detrimental problem to public health. Given the lack of remaining treatment options, 
carbapenem resistant organisms (CROs) are associated with disproportionately high rates of 
mortality and morbidity (Tian et al., 2016), (Judd, Ratliff, Hickson, Stephens, & Kennedy, 2016). 
Despite the recent trends in antimicrobial resistance, the epidemiology of CROs remains 
poorly defined at individual centers. Patient and hospital factors associated with the emergence of 
CROs are not well defined either. At the University of Pittsburgh Medical Center (UPMC) 
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Presbyterian hospital, carbapenem resistance has been identified across many common Gram-
negative bacteria. The impact that each of these Gram-negative pathogens has on patient outcomes 
as well as the overall burden of CROs at UPMC is unknown. Therefore, it was the goal of this 
study to evaluate the most common Gram-negative pathogens at UPMC Presbyterian and to gain 
an understanding of the extent of carbapenem resistance. Clinical laboratory results from the past 
16 years were evaluated to define the epidemiology of CROs, , identify associations with antibiotic 
use and CROs, and describe the characteristics and outcomes of patients with CROs. 
1.1 EPIDEMIOLOGY OF CARBAPENEM RESISTANT ORGANISMS 
1.1.1 Antimicrobial Resistance 
Antimicrobials like antibiotics, antivirals, and antifungals have been used to treat infections 
since the 1940’s. Over the past seventy-five years, treatment of infections has reduced infection-
related illness and death (CDC, 2016a). However, the cumulative toll of antimicrobial use has 
provided microorganisms with the opportunity to adapt, resulting in reduced effectiveness. 
According to the CDC, every year at least 2 million people are infected with antibiotic resistant 
organisms, and more than 23,000 people die from these infections (CDC, 2016a). 
Antimicrobial resistance can develop over time naturally due to genetic mutations or 
changes. However, antimicrobial resistance can also be amplified by the misuse or overuse of 
antimicrobials. Some examples of antibiotic misuse includes the use of antibiotics in animals to 
promote growth, underuse by patients such as stopping prior to the completion of an antibiotic, or 
misuse such as using antibiotics to treat a viral infection such as the flu (WHO, 2016). A study 
evaluating the relationship of antibiotic consumption and Gram-negative rod (GNR) hospital 
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acquired infections (HAIs) by Chen et al. showed that CR-Acinetobacter spp. was driven by broad 
spectrum antibiotic consumption (Chen et al., 2013). 
Another factor that contributes to the acceleration of AMR is the ability of antimicrobial 
resistant-microbes to spread from person to person. Infection control measures are often 
implemented to prevent the spread of AMR in the health care setting, but improper use of personal 
protective equipment and inadequate use of proper hand hygiene allows these organisms to prosper 
(Bartsch et al., 2016), (Carroll, Rangaiahagari, Musabeyezu, Singer, & Ogbuagu, 2016).   
Moreover, patients are now at the highest risk for development of AMR as ever before. The 
increasing frequency of MDROs isolation in the hospital coupled with growing at-risk populations 
(older age, critically-ill, immunosuppressed) provides ample opportunity for AMR to flourish. 
Furthermore, the emergence of new resistance mechanisms threatens our ability to treat the most 
common infectious diseases. Taken together, without effective antimicrobials, modern medical 
advancements could be mitigated by AMR. For instance, organ transplantation and other complex 
surgeries are not possible without effective antimicrobial therapies to prevent infection.  
1.1.2 Carbapenem Resistance 
Carbapenems are a class of broad spectrum, beta-lactam antibiotics. Among the beta-
lactams, carbapenems are known to have the broadest spectrum against both Gram-positive and 
Gram-negative bacteria. Additionally, they are stable against many common mechanisms of 
resistance. It is for these reasons that carbapenems are considered a last resort or last line of 
defense in treatment of resistant organisms (Papp-Wallace, Endimiani, Taracila, & Bonomo, 
2011). 
Unfortunately, the recent emergence of CROs has been shown in several studies resulting 
in increased resistance to carbapenems around the world (Gaibani et al., 2014), (Gopalakrishnan & 
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Sureshkumar, 2010), (Chouchani, Marrakchi, & El Salabi, 2011).  Carbapenem resistance has been 
noted among various Gram-negative pathogens (Heudorf et al., 2016). At our center, the most 
common Gram-negative pathogens include Enterobacteriaceae (E. coli, K. pneumoniae, E. 
cloacae, E. aerogenes, S. marcescens), Acinetobacter baumannii, and Pseudomonas aeruginosa. 
These organisms account for a significant portion of HAIs.   
1.1.3 Carbapenem Resistant Enterobacteriaceae 
Enterobacteriaceae are a family of Gram-negative, bacilli or rod-shaped bacteria that are 
responsible for almost half of all nosocomial infections annually in the United States. The most 
frequently reported species of Enterobacteriaceae include Escherichia, Klebsiella, Enterobacter, 
Proteus, Providencia, and Serratia (Miller-Keane, 2003).  
Enterobacteriaceae are components of the normal bacteria in the human microbiome. Once 
these organisms develop resistance to carbapenems, they are considered carbapenem resistant 
Enterobacteriaceae or CRE. CRE infections do not typically occur in healthy individuals. They are 
more common among hospitalized patients or individuals who reside in nursing homes or frequent 
healthcare clinics. Those with compromised immune systems, open wounds, or invasive devices 
are more likely to develop CRE infections. Infections with such organisms are extremely deadly, 
and have been reported to cause death in some 50% of all patients infected (CDC, 2016b). 
1.1.4 Acinetobacter baumannii 
Acinetobacter is a Gram-negative bacterium that is most commonly found in soil and 
water. Though there are many species of Acinetobacter, the most prominent species is 
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Acinetobacter baumannii. A. baumannii accounts for about 80% of all reported Acinetobacter 
infections (CDC, 2010). 
Similar to CRE, infection with A. baumannii is not a threat to healthy individuals. 
Hospitalized patients with weakened immune systems, open wounds, or indwelling medical 
devices are susceptible to A. baumannii infection. Transmission occurs in susceptible persons by 
means of person to person contact or contact with contaminated surfaces (CDC, 2010). Therefore, 
implementation of infection control measures is the best way to reduce the spread of this organism.  
Treatment of A. baumannii is typically chosen on a case by case basis. It is very important 
to consider underlying diseases and the patient’s current health prior to choosing treatment of this 
infection. Additionally, when treating A. baumannii it is important to consider this organism’s 
ability rapidly acquire resistance to antimicrobials (Pragasam et al., 2016), (Hsu et al., 2017). The 
overall limited treatment options for CR-A. baumannii are associated with high rates of mortality 
and poor patient outcomes. 
1.1.5 Pseudomonas aeruginosa  
Pseudomonas is a Gram-negative bacteria found widespread in the environment. The most 
common species is Pseudomonas aeruginosa (CDC, 2014). Serious infection caused by P. 
aeruginosa is most common in hospitalized patients, especially those with weakened immune 
systems. This infection in a critically ill patient can cause serious disease and even lead to death. 
At our center, CR-P. aeruginosa is more common than CRE (Buehrle et al., 2016).  
Similar to the aforementioned pathogens, once this organism develops resistance to 
carbapenems it is extremely hard to treat. Like A. baumannii, P. aeruginosa is able to rapidly 
acquire antimicrobial resistance; however, the organism also exhibits intrinsic resistance to many 
classes of antibiotics, which makes it even harder to treat (Gang & Jie, 2016). Therefore, infection 
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control measures are important in the prevention of P. aeruginosa. This organism can be spread by 
person to person contact as well as contact with a contaminated surface. Hand hygiene as well as 
personal protective equipment like gowns and gloves should be utilized to prevent spread of this 
disease. 
1.2 INCIDENCE AND PREVALENCE 
The prevalence of MDROs is dependent upon several factors. The CDC has shown that the 
prevalence of MDROs can vary by time, location, healthcare setting, and level of care (CDC, 
2009b; Jonathan R. Edwards, Margaret A. Dudeck, & Atlanta, 2006). Several studies have shown 
that ICUs, especially those within a tertiary center have higher prevalence than non-ICUs (Kollef, 
2001), (Zilahi, Artigas, & Martin-Loeches, 2016). The National Nosocomial Infection Surveillance 
(NNIS) report published in 2006 showed that prevalence of MDROs in the United States has 
increased steadily over the several preceding decades (Jonathan R. Edwards et al., 2006) 
Prior to 1992, CRE were not common in the United States. Data from the National 
Healthcare Safety Network (NHSN) showed an increase in resistant isolates among Klebsiella, and 
Escherichia in the early 2000’s. CRE is the cause of many HAIs. The CDC requires state health 
departments to complete surveillance of many types of HAIs including infections caused by CRE. 
It is through these reports that we are able to gain a better understanding of the incidence and 
prevalence of CRE. The CDC defines CRE as “resistant to imipenem, meropenem, doripenem, or 
ertapenem OR documentation that the isolate possess a carbapenemase”. Prevalence of CRE has 
increased over the past ten years through the dissemination of Klebsiella pneumoniae 
carbapenemase (KPC) (Won et al., 2011). According to the CDC, patients with KPC-producing 
CRE have been identified in every state except for two in the U.S. as of February 2016. In 
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response, state and regionally-based approaches have been implemented to effectively decrease the 
incidence of CRE (Centers for Disease & Prevention, 2013). 
MDR Acinetobacter baumannii is rarely found in the community setting. The prevalence in 
the healthcare setting, however, has increased over the last decade [CDC 2016 Multidrug-Resistant 
Acinetobacter baumannii]. The epidemiology of MDR A. baumannii is rather complex, and it is 
often the reason that this pathogen is difficult to control. Although the data may not be 
generalizable for the population, various studies have been completed to evaluate the incidence 
and prevalence of CROs. One study evaluated various publications to show an incidence of MDR 
Acat to be 0.14 (95% CI, 0.136-0.161) per 1,000 patient days at risk [Nelson RE et. al. 2016].  
MDR-P. aeruginosa is the most common resistant pathogen [NNIS 2004, Fernandez-Barat 
2016]. In 2012, a study was completed to evaluate the epidemiology of MDR- and CR-P. 
aeruginosa in children, and the results showed an increased prevalence of MDR- and CR-P. 
aeruginosa in this patient population [Logan et al 2012]. Another study completed in 2016 showed 
that P. aeruginosa is the most common cause of ICU-acquired pneumonia, and a high prevalence 
of MDR is seen within this population [Fernandez-Barat 2016].  
1.3 RISK FACTORS 
Many studies have been completed over the last decade to evaluate risk factors for MDROs 
and CROs. One prominent finding in the literature is best stated by Chaisathaphol and 
Chayakulkeeree from their study in 2014: “the strongest risk factor for acquiring MDR Gram-
negative infection was previous antibiotic use” (Chaisathaphol & Chayakulkeeree, 2014). Various 
other studies support this statement that prior antibiotic use is a risk factor for MDROs, and ICU 
admission as well as age >65 were common risk factors among these studies (Brotfain et al., 2016; 
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Tun et al., 2016; Tuon et al., 2012). A study in 2016 on MDR- A. baumannii showed that age >65, 
chronic obstructive pulmonary disease, and Acute Physiology and Chronic Health Evaluation II 
(APACHE-II) score higher than 20 were all independent risk factors (Brotfain et al., 2016). 
Similarly, other research supports that critically ill patients have an increased risk of developing 
CROs. Furthermore, having a solid organ transplant is a risk factor for many infectious diseases 
including but not limited to bacteremia, sepsis, pneumonia, and urinary tract infections (Donnelly 
et al., 2016), (Lalueza et al., 2016). Another study from 2012 showed that admission to an ICU, 
higher leukocyte counts, and previous carbapenem use were statistically associated with CR-P. 
aeruginosa (Tuon et al., 2016). Although the risk factors are typically evaluated by type of 
pathogen causing the infection, it is evident that many risk factors overlap.  
1.4 TREATMENT 
Treatment of MDROs is extremely difficult and ever-changing as these organisms evolve. 
Carbapenems are commonly used to treat infections caused by MDROs. However, the overuse of 
carbapenems over time is thought to have contributed to the development of CROs (Tuon et al., 
2016).  
1.4.1 Treatment Options and Outcomes 
Treatment of CROs varies widely from center to center as each center attempts to best treat 
their patient population. Moreover, treatment options for CROs have evolved over time. Initial 
treatment of CROs was with the use of a single antibiotic, which is referred to as monotherapy. 
Unfortunately, most medications used to treat CROs individually were toxic salvage agents like 
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aminoglycosides, polymyxins, and tigecycline. Regardless of treatment choice, there were 
concerns for efficacy, increasing resistance, and toxicities (van Duin, Kaye, Neuner, & Bonomo, 
2013).  Due to poor response rates of monotherapy, the use of antibiotic combinations to treat 
CROs has become the new standard. Combination regimens typically include a carbapenem in 
combination with one or more salvage agents.  Most recently, however, new agents have been 
developed with activity against CROs, highlighting a new era in treatment of CROs. The most 
recently approved antibiotic for the treatment of CRE is a combination drug called Ceftazidime-
Avibactam. It was approved in the United States in 2015. Although the drug appears to be a safe 
and effective treatment option, resistance to this antibiotic has already been documented in the 
United States (Shields et al., 2016). 
Other treatment options for these patients involve investigational drugs, there are three 
primary groups working to gain FDA approval. Carbavance® is one of the antibiotics currently 
pursuing FDA approval. It is a drug being produced by The Medicines Company. Carbavance® is 
a combination therapy that uses an already existing carbapenem called Meropenem in combination 
with Vaborbactam. Data suggest that Carbavance® is effective for the treatment of CRE causing 
complicated Urinary Tract Infection (cUTI) (Wire, 2016). Additionally, a phase three study is well 
underway for the use of Carbavance® to treat complicated Intra-abdominal Infection (cIAI), 
bacteremia, and both Healthcare-Associated and Ventilator-Associated Bacterial 
Pneumonia(HABP/VABP). It is estimated to hit the market as early as 2017. 
Shionagi is a company working to develop S-649266. This drug is a cephalosporin that is 
being used in investigational studies for the treatment of carbapenem resistant gram-negative 
pathogens (CRGNP) causing cUTI, sepsis/bacteremia, HABP, and VABP. Enrollment for the 
phase 3 study began in 2016. 
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Plazomicin® is the third antibiotic currently being tested through clinical trials. Achaogen 
is the company developing this drug. Similar to the two aforementioned antibiotics, Plazomicin is 
being developed for the treatment of CRE causing cUTI, sepsis/bacteremia, HABP, and VABP. 
Overall, the development of new antibiotics that are effective at treating CROs and well 
tolerated is novel. Treatment has improved over time, and it continues in that direction as the 
demand for such antibiotics increases. Nevertheless, the emergence of further resistance upon the 
introduction of these agents into the clinic suggests that AMR will be a continuing problem. 
Understanding the epidemiology of CROs at individual centers will allow detection of trends and 
an attempt to prevent further spread of these organisms. 
There is large push for new treatment options as the prevalence of these organisms 
continues to increase. Resistance to all available antibiotics is a growing concern. However, the 
need for treatment options cannot wait for these results as current treatments are associated with 
overall poor outcomes (van Duin et al., 2013). 
1.5 PUBLIC HEALTH SIGNIFICANCE 
CROs are associated with higher rates of mortality and morbidity than those with 
susceptible strains (CDC, 2013). In addition to mortality rates, extended length of hospitalization 
as well as increased hospital costs are large public health concerns.  
The CDC has deemed CRE to be a global threat as of 2013. CRE along with other 
antibiotic resistant organisms are reaching extremely high levels around the world. Antimicrobial 
resistance has been identified in every region of the world (WHO, 2016). There is a global need to 
change the way in which antibiotics are used and prescribed. Additionally, there is a global need 
for implementation of infection control programs and new treatment options.  
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Every year in the United States at least 23,000 deaths occur from infections caused by 
antibiotic resistant organisms. More than $30 billion is spent on treating these drug-resistant 
infections annually (CDC, 2013). The economic burden of CRE was further evaluated by Bartsch 
et al. in 2016. They found that the median cost of a single CRE infection can range from $22,484-
$66,031 for hospitals, $10,440-$31,621 for third-party payers, and $37,778-$83,512 for society 
(Bartsch et al., 2016).  They also found that the annual cost of CRE outweighs the annual cost of 
many other chronic and acute diseases. Another study estimated the costs for MDR A. baumannii 
to range from $33,510- $129,917 per infection (Nelson et al., 2016). 
Although MDR pathogens are typically associated with nosocomial infections, the 
prevalence of these organisms in the community is increasing (van Duin & Paterson, 2016). 
Various studies have shown the spread of MDR pathogens from procedures such as hemodialysis, 
bronchoscopies, and gastroscopies (Bajolet et al., 2013; Vincenti et al., 2014). This type of 
transmission has provided different risk factors than nosocomial infections of these organisms, and 
occurrence has even been noted among healthy individuals (van Duin & Paterson, 2016).  
Despite recent global trends, the epidemiology of CROs at individual centers remains 
poorly defined. Patient and hospital factors associated with the emergence of CROs are also 
unclear at this time. Various studies have been completed, but the data lacked power due to the 
small sample sizes or short time frames that were evaluated. Gaining a site-specific impact of these 
organisms can help identify where continued antibiotic management and infection control efforts 
should be focused. Additionally, understanding individual site impact of CROs could help 
illustrate the deafening need for new treatment options and reduce the public health burden of this 
burgeoning problem.  
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2.0  OBJECTIVES 
Similar to many other centers in the US, previously susceptible Gram-negative pathogens 
have been identified as carbapenem-resistant at UPMC Presbyterian.  However, the overall burden 
and epidemiology of CROs is unknown. Therefore, we evaluated CROs among the most common 
Gram-negative pathogens at this tertiary center. The primary objective of the study was to define 
the epidemiology of CROs over a 16-year period. To achieve the primary objective, our specific 
aims included defining the incidence of of CROs at UPMC Presbyterian, identifying associations 
between trends in antibiotic use and the emergence of CROs, and further describing characteristics 
and outcomes of patients with CROs. 
The hypotheses of this study were: 
H1: Carbapenem resistance has emerged over time across many pathogens at UMPC 
Presbyterian hospital. 
H2: Increased carbapenem usage is associated with increasing rates of CROs at UPMC 
Presbyterian hospital. 
H3: Patient outcomes vary by pathogen, severity of illness, and underlying diseases. 
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3.0  METHODS 
3.1 ETHICS STATEMENT 
This study was approved by the Institutional Review Board (IRB) at the University of 
Pittsburgh. The IRB waived the need for written informed consent from participants due to the 
nature of the study. The study was a retrospective observational study that involved very minimal 
risk to subjects involved in the research, intentional deception of participants was not involved, nor 
did the research involve a vulnerable population. The waiver provided for subjects does not have 
any adverse effects on the right and welfare of the subjects involved. 
3.2 HOSPITAL SETTING AND DEFINITIONS 
UPMC Presbyterian Hospital is a tertiary center located in Pittsburgh, Pennsylvania with 
792 licensed beds. Intensive care units (ICUs) account for more than 15% (122) of all beds. UPMC 
Presbyterian’s specialties include cardiology, gastroenterology, neurosurgery, organ 
transplantation, and trauma.   
The MISYS-SUNQUEST Laboratory Information System at UPMC was used to extract 
clinical microbiology data as well as demographic information throughout the study, and no 
changes were made to the system during the study timeframe (2000-2015). The medical archival 
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system (MARS) data repository was utilized for underlying conditions such as transplant status. 
Antibiotic exposure data was extracted the UPMC pharmacy data warehouse, and antibiotic daily 
defined doses (DDDs) were calculated based on the methods and conversion standard that the 
WHO Collaborating Center for Drug Statistics Methodology has created. Specifically, DDDs are a 
unit of measurement that represents the average daily dose of a drug used(WHO-CCDSM, 2016). 
Utilizing DDDs provides a standardization of antibiotic consumption across centers.  Additionally, 
DDDs enable researchers to identify trends in drug use over time in different settings. At UPMC 
Presbyterian, the DDD calculation was based on patient charge data. The number of units is 
calculated over time for each antibiotic using the WHO DDD conversion formula. This value is 
standardized by 1,000 patient days.  
Only isolates that were tested for carbapenem susceptibility were included in these 
analyses. A unique patient was identified by the patient’s first CR-pathogen. Recurrence was 
defined as isolation of another CRO pathogen after 90 days from the index case had lapsed.  For 
pathogen-specific analysis, patients were re-included in more than one CRO was identified. For 
outcome analysis, patients were included only once and classified according to the first CRO 
recovered.  Patient records were linked to the Social Security Death Index (SSDI) to determine 
time from CRO culture to death.  
3.3 BACTERIAL ISOLATES 
Isolates were identified by the UPMC clinical microbiology laboratory using standard 
methods. Only isolates collected from patients in the hospital were included; isolates collected 
from patients in outpatient locations were excluded from data analysis. Susceptibility testing was 
performed by Kirby-bauer disc diffusion and/or standard automated methods (Microscan). Results 
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were interpreted using the most recent Clinical and Laboratory Standards Institute (CLSI) 
definitions shown in Tables 1-3 (CLSI, 2015). We defined CROs as any targeted pathogen 
demonstrating non-susceptibility (Intermediate or Resistance interpretation) to any carbapenem. 
Table 1. CLSI 2015 carbapenem defined breakpoints Enterobacteriaceae 
Antimicrobial 
Agent 
Zone Diameter Interpretive 
Criteria (nearest whole mm) 
MIC interpretive Criteria 
(µg/mL) 
S I R S I R 
Doripenem ≥23 20-22 ≤19 ≤1 2 ≥4 
Ertapenem ≥22 19-21 ≤18 ≤0.5 1 ≥2 
Imipenem ≥23 20-22 ≤19 ≤1 2 ≥4 
Meropenem ≥23 20-22 ≤19 ≤1 2 ≥4 
a. Breakpoints are defined as susceptible (S), intermediate (I), or resistant (R). 
Table 2. CLSI 2015 carbapenem defined breakpoints Pseudomonas aeruginosa 
Antimicrobial 
Agent 
Zone Diameter Interpretive 
Criteria (nearest whole mm) 
MIC interpretive Criteria 
(µg/mL) 
S I R S I R 
Doripenem ≥19 16-18 ≤15 ≤2 4 ≥8 
Imipenem ≥19 16-18 ≤15 ≤2 4 ≥8 
Meropenem ≥19 16-18 ≤15 ≤2 4 ≥8 
a. Breakpoints are defined as susceptible (S), intermediate (I), or resistant (R). 
Table 3. CLSI 2015 carbapenem defined breakpoints Acinetobacter spp. 
Antimicrobial 
Agent 
Zone Diameter Interpretive 
Criteria (nearest whole mm) 
MIC interpretive Criteria 
(µg/mL) 
S I R S I R 
Doripenem ≥18 15-17 ≤14 ≤2 4 ≥8 
Imipenem ≥22 19-21 ≤18 ≤2 4 ≥8 
Meropenem ≥18 15-17 ≤14 ≤2 4 ≥8 
a. Breakpoints are defined as susceptible (S), intermediate (I), or resistant (R). 
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3.4 STATISTICAL ANALYSES 
Incidence rates were calculated as the total number of pathogen specific CROs per 1000 
patient days. Linear regression was used to compare carbapenem resistance and antibiotic DDDs 
over time. Time series, cross correlation regression analysis was used to determine rates of CROs 
as a function of DDDs. Rates of 30- and 90-day mortality were determined from time of first CRO 
isolation.  Kaplan-Meier curves were used to plot survival over time. The curves were compared 
by log-rank test among CROs.  
Chi-square tests were used in univariate analysis to identify predictors of death. Continuous 
and categorical variables were compared by student’s t-test and chi-square respectively. The 
factors tested included age, gender, location, culture source, and organism.   
In multivariate analysis, a logistic regression model was built with stepwise backward 
selection procedures using variables with a p-value <.10.  Using beta-coefficients from the logistic 
regression model, a prediction equation was derived by fitting the data to an inverse probability 
equation. Area under the curve (AUC) was evaluated using a receiver operating characteristic 
(ROC) curve.  
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4.0  RESULTS 
4.1 EPIDEMIOLOGY OF CROs AT UPMC 
Among targeted pathogens, 84,597 isolates from 37,823 unique patients were identified 
during the study period (Figure 1).  E. coli was most common, followed by P. aeruginosa and K. 
pneumoniae.  Overall, 9.5% (8,864/84,597) of isolates were classified as CR (Figure 2).  Rates of 
resistance were highest for P. aeruginosa and lowest for E. coli.  P. aeruginosa accounted for 58% 
of all targeted CROs.  
 
Figure 1. Gram-negative pathogens at UPMC Presbyterian (n=84,597) 
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The proportion of isolates that were CR increased significantly from 2000 to 2015 
(P<0.001). A significant increase in CR was also noted from 2000-2015 among Acat, Ent, and 
Klpn isolates (P<0.0001). Conversely, CR among Psar isolates decreased significantly over the 
study duration (P<0.0001) (Table 4).  
 
 
 
 
 
 
 
Figure 2. Carbapenem resistant pathogens at UPMC Presbyterian (n=8,864) 
Table 4. Carbapenem Resistance Rates per 1,000 Patient Days - UPMC Presbyterian 2000-2015 
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Figure 3 illustrates the number of unique patients (4,994) by pathogen from 2000 to 2015. 
Data shows that Psar was the most common CR pathogen for all years (2000-2015). However, 
other CROs emerged in waves as the second most common CR pathogen. Waves included CRAcat 
in 2010, followed by CR-Klpn in 2012 and CR-Ent in 2014.   
 
 
Figure 4 represents percent carbapenem resistance by pathogen over time. Psar had the  
 
Figure 3. Unique patient CROs by pathogen at UPMC Presbyterian (2000-2015)  
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Rates of carbapenem resistance also changed significantly over time (Figure 4).  Psar 
demonstrated the highest rates of baseline CR; however, from 2007 forward rates of CR among 
Acat were highest. Notably, CR emerged among previously susceptible pathogens, including Klpn, 
Ent, and Serm. In 2015, rates of CR exceeded 10% for every pathogen except Ecol.  
 
 
 
Figure 4. Carbapenem resistance by pathogen at UPMC Presbyterian (2000-2015) 
 21 
Recurrence among patients with Psar was more common than any other pathogen. For 
these patients, recurrence was most commonly due to re-isolation of Psar after 90 days. On the 
other hand, 16% of patients who initially had CR-Klpn had a second CRO pathogen identified 
(Figure 5).  
 
 
 
4.2 ANTIBIOTIC USAGE AT UPMC 
Carbapenem DDD’s increased significantly from 2000-2015 (P<0.001) as shown in Figure 6. 
Increased rates of carbapenem DDDs paralleled patterns identified among the emergence of CROs.  
Indeed, cross-correlation analysis demonstrated a zero-lag time difference between the two 
(R2=0.90, P<0.001) (Figure 7).  By pathogen, only Acat showed a time variance of -3 years 
suggesting the increases in carbapenem use were due, in part, to an increased frequency of CR-
Acat isolation (R2=0.61)(Table 5). Taken together, however, the cumulative data indicate that 
increased consumption of carbapenems and the emergence of CROs occurred simultaneously.  
Figure 5. 90-day Recurrence rates by type of pathogen UPMC Presbyterian 200-2015 
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We further evaluated trends among DDDs for other antibiotic classed, but did not identify 
any associations with the emergence of CROs at our center (data not shown). 
 
 
Figure 6. Carbapenem DDD use- UPMC Presbyterian 2000-2015 
 
 
 
 
Figure 7. Cross correlation of DDD use with emergence of CROs UPMC Presbyterian 2000-2015 
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Table 5. Cross Correlation of DDDs by pathogen 
 
LAG R-squared 
ACAT -3 0.61 
ECOL 0 0.89 
ENT 0 0.85 
KLPN 0 0.88 
PSAR 0 0.86 
SERM 0 0.63 
TOTAL 0 0.91 
4.3 PATIENT CHARACTERISTICS 
CROs were identified from 4,994 unique patients. Table 6 below describes the 
characteristics of these patients. 
 
 
 
 
Table 6. Characteristics of patients with CROs at UPMC Presbyterian 2000-2015 
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Twenty-six percent of patients were transplant recipients. . Transplant types included lung 
(51%), liver (23%), intestine (10%), kidney (8%), heart (5%), and other types (3%).  Psar was 
more common among transplant recipients than non-transplant recipients (P<0.001). Conversely, 
CR-Acat was more common among non-transplants (P<0.001, Table 7). 
 
Table 7. Pathogen Distribution by Transplant Status - UPMC Presbyterian 2000-2015 
Pathogen  
Transplant Patients 
(n=1,402) 
Non-Transplant Patient 
(n=3,592) 
ACAT 8.32% 13.01% 
ECOL 2.54% 5.38% 
ENT 5.55% 11.23% 
KLPN 16.04% 14.66% 
PSAR 64.15% 53.07% 
SERM 3.39% 2.65% 
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4.4 MORTALITY 
Overall 30- and 90-day mortality rates were 19% and 32%, respectively.  
4.4.1 Predictors of Mortality 
Age (OR=1.02, 95% CI:1.02-1.03, P<0.001) and ICU residence (OR=3.63, 95% CI:3.10-
4.26, P<0.001) were independent predictors of 30d mortality illustrated in Table 8. On the other 
hand, receipt of a solid organ transplant was protective (P<0.001).  
 
Table 8. Predictors of 30-day Mortality among Patients with CROs 
Factor Alive (n=4,022)   Dead (n=972)   P-value 
Male, n (%) 2,237 (55.6) 574 (59.1) 0.09 
Age > 65, n (%)  226 (5.6) 406 (41.8) <0.0001 
Residence in ICU, n (%)  1,410 (35.1) 654 (67.3) <0.0001 
Transplant recipient, n (%) 1,104 (27.4) 193 (19.9) 0.002 
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Specifically, patients who received intestinal and lung transplants had significantly 
different 30d mortality rates as compared to non-transplanted patients (P<0.001 for both). All non-
lung transplant patients also had a significantly different 30d mortality rate compared to non-
transplants (Figure 8).  
 
21.07%
14.88%
12.59%
16.83%
9.84%
18.27%
14.92%
23.26%
17.24%
0%
5%
10%
15%
20%
25%
Non-txp All txp Lung Liver Intestine Kidney Heart Other Non-lung
txp
 
Figure 8. 30-day Mortality Rates by Transplant Type UPMC Presbyterian 2000-2015 
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By pathogen, mortality rates at 30d were higher for Acat compared to all organisms (28%, 
P<0.001), and lower for Psar compared to all organisms (17%, P<0.001, Figure 9). Rates ranged 
by culture site from 27% (blood) to 12% (urine, P<0.001, Figure 10).  
 
 
  
 
 
 
 
Figure 9. 30- and 90- day Mortality Rates by CR-Pathogen UPMC Presbyterian 2000-2015 
Figure 10. 30- and 90- day Mortality Rates by Culture Site UPMC Presbyterian 2000-2015 
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4.4.2 Survival Outcomes 
In keeping with our univariate analysis, Acat was associated with lower rates of survival 
compared to all other pathogens at 30- and 90-days (Figures 11 and 12). Psar was associated with 
higher rates of survival compared to Acat (P<.0001) and Klpn (P<.05). 
 
 
 
 
 
Figure 12. 90-day Survival Curves by CR-pathogen UPMC Presbyterian 2000-2015 
 
 
Figure 11. 30-day Survival Curves by CR-pathogen UPMC Presbyterian 2000-2015 
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p=  
Using logistic regression, we compared the risk of death for all variables (Table 9), and 
used coefficients from our model to derive 30-day mortality prediction equation (Figure 13).  
 
Table 9. Independent predictors of 30-day Mortality UPMC Presbyterian 2000-2015 Mortality Prediction 
Model 
Variable β-coefficient   P-value 
Intercept -4.03  <0.001 
Age 0.02  <0.001 
Male 0.11   0.14 
ICU 1.29  <0.001 
SOT -0.31  <0.01 
Organism 
ACAT 0.27  0.24  
ECOL -0.28  0.32  
ENT -0.24  0.33  
KLPN 0.07  0.75  
PSAR -0.19  0.38  
Culture 
RESP 0.86  0.26  
URINE 0.51  0.50  
DWOUN 0.82  0.28  
BLOOD 1.20741 0.115  
SWOUN 1.002972 0.210  
 
 
 
 
 
Figure 13. 30-day Mortality Prediction Equation 
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4.4.3 Mortality over Time 
Annual mortality rates by pathogen were evaluated from 2007 to 2015, following the 
emergence of CR-Acat and CRE (Figure 14).  Rates of 30-day mortality did not change 
significantly for Psar during this time period (R2=.15, P=NS). On the other hand, the cumulative 
30-day mortality rate of all other pathogens decreased from 28% in 2007 to 21% in 2015 (R2=0.73, 
P=.003) (Figure 15). 
 
 
Figure 14. 30-day Mortality by Pathogen since 2007 UPMC Presbyterian 2000-2015 
 
 
Figure 15. 30-day Mortality PSAR vs Non PSAR since 2007 UPMC Presbyterian 2000-2015 
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5.0  DISCUSSION 
5.1 CARBAPENEM RESISTANCE EMERGES IN WAVES OVER TIME 
We hypothesized that carbapenem resistance has emerged over time across many 
pathogens at our center, and our analyses supported these hypotheses. We found a statistically 
significant increase in CROs from 2000 to 2015. Psar consistently accounted for the largest 
number of unique patients with CROs.  Furthermore, the emergence of other pathogens occurred at 
different time points over the surveillance period. Some of the emerging waves that were noted 
include Acat in 2010, Klpn in 2012, and Ent. in 2014. 
Various theories could be considered for the cause of these emerging waves. One theory 
could be that once a pathogen specific outbreak is identified, targeted infection control 
investigations are launched to prevent the transmission of that pathogen. While infection 
preventionists are implementing strict surveillance in a specified location, the focus on one 
organism may distract staff from noticing an increase of another organism. This could be 
especially true if the secondary pathogen has been previously undetected.  
Another theory that could account for the emergence of CROs is that diagnostics related to 
surveillance and identification have improved over time due to familiarity with these pathogens. 
Although we attempted to eliminate this potential confounder by retrospectively applying the 
2015CLSI breakpoints, it is still a conceivable cause of the emerging waves of CROs that were 
identified. It is also possible that clinical standards in terms of surveillance could have changed 
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over the study duration. More specifically, if surveillance for these organisms increased over time 
we would expect to identify more CROs.  
Consistent with the results of previous research, we hypothesized that antimicrobial usage 
would be associated with the emergence of carbapenem resistance at our center. DDDs of all 
classes of antibiotics were evaluated. We saw a significant increase in carbapenem use over the 
study duration. Conversely, a significant decrease in fluoroquinolone use was noted over time. 
This decrease in fluoroquinolone use is thought to be the result of antibiotic management which 
was implemented at UPMC in 2001.  
When we compared the increase in carbapenem use to the increase of CROs, we did not see 
a causal relationship as expected. Prior research suggests that an increase in CROs would be 
expected after an increase in carbapenem use (Tun et al., 2016; Tuon et al., 2012). Instead, we 
concluded both the emergence of CROs and increased rates of carbapenem DDDs occurred 
simultaneously. Given that previous research does not agree with our findings, we were forced to 
consider alternative explanations. It is possible that 1-year time intervals may not have been 
sensitive enough to detect a subtle relationship.  
One potential explanation for the emergence of CROs at our center is the level of care 
provided at our center. Given that we are a tertiary care center, there could be a higher number of 
patients coming into the center who are critically ill and could be housing these organisms prior to 
admission. One specific patient population to consider is those patients who are admitted from a 
nursing home or skilled nursing facility due to the acuity of care among this population.  These 
patients are often colonized with MDROs, and upon admission to our center the organisms are 
provided with the opportunity to spread throughout our facility.  
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Another potential reason for the emergence of CROs at our center is geographic location. 
As the CDC suggest in their 2006 report, MDROs can be endemic. Western Pennsylvania sits 
within an endemic region of the United States for both CRE and CR Acat (CDC 2016).  
5.2 CROs ARE ASSOCIATED WITH HIGH RATES OF MORTALITY  
We hypothesized that patient outcomes vary by pathogen, severity of illness, and 
underlying diseases. We found that CROs are associated with high rates of mortality at our center. 
We further evaluated specific factors in order to better define which factors were potentially 
predictors of mortality.  
Based on previous research, we anticipated that age >65 and residence in the ICU at time of 
culture isolation would both be associated with increased mortality (CDC, 2009a, 2009b; 
Chaisathaphol & Chayakulkeeree, 2014). We anticipated that age >65 could be a predictor of 
mortality as increased age alone is associated with higher mortality rates. Additionally, residence 
in the ICU is an expected predictor of mortality as patients in the ICU are critically ill and have 
increased comorbidities as well as invasive devices such as catheters or mechanical ventilation.  
Among all pathogens, Acat was associated with the highest mortality rates. Acat is not a 
threat for healthy individuals; instead, Acat is known to affect those with chronic lung disease, 
diabetes, and weakened immune systems (Brotfain et al., 2016; Hsu et al., 2017). Multi-drug 
resistant Acat is considered to have an increased virulence that is associated with high rates of 
mortality (Stahl, Bergmann, Gottig, Ebersberger, & Averhoff, 2015; Thummeepak, Kongthai, 
Leungtongkam, & Sitthisak, 2016). Additionally, Acat was noted in several studies to be most 
commonly expressed in respiratory and blood infections which we know to have the highest 
mortality rates (Fujikura et al., 2016; Shields et al., 2012; Tsioutis et al., 2016). 
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Among culture sites, blood cultures were associated with the highest mortality rates. This 
was an expected finding. Although patients can be colonized with pathogens, this is not typically 
the case for blood culture sources. If the pathogen is identified in the blood, this is an infection and 
the patient will receive treatment. Other sources like urine and respiratory cultures are more likely 
to show the presence of a pathogen without the presence of symptoms or infection. These patients 
could be colonized, and a colonized patient who is asymptomatic would not receive treatment. 
Unlike the respiratory tract, blood is considered sterile. The presence of a microorganism in the 
blood typically elicits a profound immune response. This type of response to infection can lead to 
complications like sepsis.  Furthermore, bloodstream infections are often associated multi-organ 
failure which contributes to increased mortality rates (CDC, 2016c). Since all positive blood 
cultures are true infections, we would expect CROs identified in the blood to be associated with 
higher mortality rates.   
As found in previous studies, mortality rates did not vary between sex, which was also 
expected as previous studies do not suggest any correlation between sex and CRO mortality 
(Chaisathaphol & Chayakulkeeree, 2014; Shields et al., 2012; Tian et al., 2016).   However, SOT 
was the only factor that resulted in an unexpected outcome. We found that SOT recipients had 
significantly lower rates of mortality (P<.05). 
Solid-organ transplant recipients are a very unique population. This patient population is 
immunosuppressed in order to prevent rejection of the transplanted organ. Due to the increased 
risk of infection and mortality, we did not anticipate SOT to be a protective factor. Discovering 
that SOT patients at our center had a significantly lower mortality rate was rather surprising.  
One theory to consider involves the Transplant and Infectious Diseases (TID) group at 
UPMC. These physicians are devoted to preventing infectious diseases in the SOT patient 
population, and accordingly undertakes active surveillance measures to identify infections early in 
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the disease course. They also aim to treat these patients as effectively as possible and often utilize 
prophylaxis. By treating SOT patients with prophylaxis at the time of transplant, this could 
potentially mitigate severe symptoms and help to improve this patient population’s outcomes. 
Overall, the increased surveillance and treatment could potentially account for the lower mortality 
rates in this population. 
Another potential reason for SOT being protective for mortality may be related to chronic 
colonization. One limitation to the data are that a positive culture does not delineate between 
infection and colonization. Patients experiencing an infection are symptomatic and require 
treatment. Colonized patients, conversely, are often asymptomatic and do not require treatment. 
Colonization typically occurs due to previous infection or increased exposure. SOT recipients 
frequent health care facilities and have an increased exposure to these organisms. Therefore, the 
likelihood of colonization could be higher in SOT recipients driving the outcomes to appear as 
protective.  
CR-pathogen type among SOT recipients was another factor that we took into 
consideration. We found that CR-Psar was more common among SOT recipients. This is 
significant given that CR-Psar is associated with the lowest mortality rates. Therefore these lower 
rates could be driving the lower mortality rates among SOT recipients.  
Additionally we were interested in which types of SOTs were developing CROs. Our 
center specializes in organ transplantation and has a very high volume of lung transplantations. 
Therefore, it was no surprise to find more than half of SOT recipients with CROs were lung 
transplant recipients.  Although it was not an a priori hypothesis, we did expect that mortality rates 
would improve over time.  One reason that we anticipated a decrease in mortality over time is due 
to new antibiotic availability. Various new antibiotics became available throughout the duration of 
this study. Some of the antibiotics that were FDA approved between 2001 and 2016 include but are 
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not limited ceftolozane-tazobactam (2014) and ceftazidime-avibactam (2015). Having new 
antibiotics available would help decrease mortality as patients are more likely to respond to a new 
antibiotic than an antibiotic that they may have developed resistance to from previous use. 
Antibiotic management is another potential explanation for the decrease in mortality over 
time. At our center, antibiotic management was implemented in 2001. The purpose of antibiotic 
management is to oversee the prescription of antibiotics in order to prevent misuse and overuse of 
antibiotics. Additionally, this group has created algorithms over time that continues to allow 
refinement and improvement of treatment approaches over time. A recent study showed that 
antibiotic stewardship programs can decrease length of stay as well as 30-day readmission rates; 
overall they were shown to have a clinical benefit (Lee et al., 2016). 
Another reason that mortality has improved over time could be due to improved diagnostics 
within the microbiology laboratory. Specifically, in 2015 the CLSI breakpoints were redefined. 
Fortunately, the antibiotic management program analyst designed and implemented a process to 
enable the application of these breakpoints retrospectively to ensure inclusion of all CR isolates in 
the same fashion. Given that the new breakpoints are more sensitive, there is a chance that a 
proportion of patients received inappropriate antibiotic therapy. In turn, the increased risk of 
inappropriate treatment in previous years could have led to increased mortality. 
One of our primary aims was to develop a prediction model for patient mortality. Using 
coefficients from the logistic regression model, we were able to create a prediction model for 
patient mortality.  A major benefit of having a prediction model would be related to treatment. 
Clinicians would be able to prospectively predict patient mortality. Having this type of information 
at baseline could be extremely beneficial for tracking a center’s improvement in treating these drug 
resistant organisms.  In theory, upon isolating a CRO one would simply enter the patient specific 
data for each factor within the model which includes the following: age, sex, hospital location, 
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SOT, pathogen type, and source type. Upon entering these data, the model would calculate a 
predicted mortality for that patient. 
The primary strength of this study was its longitudinal nature and detailed patient-level 
data. Having such a large dataset provides a better understanding of the trends and epidemiology 
of CROs at our center. Additionally, standardization of the data over the time period was a great 
strength of this study. Some of the limitations included the lack of delineation between infection 
and colonization among CROs and the inability to classify severity of illness at the individual 
level.  
In conclusion, this study found that CROs emerge in waves over time. We were able to 
define the epidemiology of these organisms at our center and gain an understanding of specific 
factors related to the emergence of CROs. We showed that there is no association between 
carbapenem DDDs and the emergence of CROs. Additionally, we were able to identify predictors 
of mortality, and utilize the data to create a prediction model which is the first of its kind. These 
findings have substantial public health significance as they provide a foundation for center-specific 
epidemiology of CROs. 
 38 
BIBLIOGRAPHY 
Bajolet, O., Ciocan, D., Vallet, C., de Champs, C., Vernet-Garnier, V., Guillard, T., . . . Bureau-
Chalot, F. (2013). Gastroscopy-associated transmission of extended-spectrum beta-
lactamase-producing Pseudomonas aeruginosa. J Hosp Infect, 83(4), 341-343. doi: 
10.1016/j.jhin.2012.10.016 
Bartsch, S. M., McKinnell, J. A., Mueller, L. E., Miller, L. G., Gohil, S. K., Huang, S. S., & Lee, 
B. Y. (2016). Potential economic burden of carbapenem-resistant Enterobacteriaceae 
(CRE) in the United States. Clin Microbiol Infect. doi: 10.1016/j.cmi.2016.09.003 
Brotfain, E., Borer, A., Koyfman, L., Saidel-Odes, L., Frenkel, A., Gruenbaum, S. E., . . . Klein, 
M. (2016). Multidrug Resistance Acinetobacter Bacteremia Secondary to Ventilator-
Associated Pneumonia: Risk Factors and Outcome. J Intensive Care Med. doi: 
10.1177/0885066616632193 
Buehrle, D. J., Shields, R. K., Clarke, L. G., Potoski, B. A., Clancy, C. J., & Nguyen, M. H. 
(2016). Carbapenem-resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for 
Mortality and Microbiologic Treatment Failure. Antimicrob Agents Chemother. doi: 
10.1128/AAC.01243-16 
Carroll, M., Rangaiahagari, A., Musabeyezu, E., Singer, D., & Ogbuagu, O. (2016). Five-Year 
Antimicrobial Susceptibility Trends Among Bacterial Isolates from a Tertiary Health-Care 
Facility in Kigali, Rwanda. Am J Trop Med Hyg, 95(6), 1277-1283. doi: 10.4269/ajtmh.16-
0392 
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 
Healthcare Infection Control Practices Advisory Committee. (2009a). Epidemiology of 
MDRO's. 2016, from https://www.cdc.gov/hicpac/mdro/mdro_3.html 
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 
(2009b). MDRO Prevention and Control.  
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 
(2010). Acinetobacter in Healthcare Settings.  
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 
(2013). Drug Resistance Threat Report 2013.  
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 
(2014). Pseudomonas in the Healthcare Setting. from 
https://www.cdc.gov/hai/organisms/pseudomonas.html 
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 
(2016a). Antibiotic/Antimicrobial Resistance. from https://www.cdc.gov/drugresistance/ 
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 
(2016b). Carbapenem-resistant Enterobacteriaceae in Healthcare Settings.  
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 
(2016c). Sepsis.  
 39 
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. 
(2013). Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb Mortal Wkly 
Rep, 62(9), 165-170.  
Chaisathaphol, T., & Chayakulkeeree, M. (2014). Epidemiology of infections caused by 
multidrug-resistant gram-negative bacteria in adult hospitalized patients at Siriraj Hospital. 
J Med Assoc Thai, 97 Suppl 3, S35-45.  
Chen, I. L., Lee, C. H., Su, L. H., Tang, Y. F., Chang, S. J., & Liu, J. W. (2013). Antibiotic 
consumption and healthcare-associated infections caused by multidrug-resistant gram-
negative bacilli at a large medical center in Taiwan from 2002 to 2009: implicating the 
importance of antibiotic stewardship. PLoS One, 8(5), e65621. doi: 
10.1371/journal.pone.0065621 
Chouchani, C., Marrakchi, R., & El Salabi, A. (2011). Evolution of beta-lactams resistance in 
Gram-negative bacteria in Tunisia. Crit Rev Microbiol, 37(3), 167-177. doi: 
10.3109/1040841X.2011.552880 
CLSI. (2015). CLSI Breakpoints. In C. a. L. S. Institute (Ed.), (Vol. 2015-2016). 
Donnelly, J. P., Locke, J. E., MacLennan, P. A., McGwin, G., Jr., Mannon, R. B., Safford, M. M., . 
. . Wang, H. E. (2016). Inpatient Mortality Among Solid Organ Transplant Recipients 
Hospitalized for Sepsis and Severe Sepsis. Clin Infect Dis, 63(2), 186-194. doi: 
10.1093/cid/ciw295 
Fujikura, Y., Yuki, A., Hamamoto, T., Ichimura, S., Kawana, A., Ohkusu, K., & Matsumoto, T. 
(2016). Evaluation and validity of a polymerase chain reaction-based open reading frame 
typing method to dissect the molecular epidemiology for Acinetobacter baumannii in an 
epidemiologic study of a hospital outbreak. Am J Infect Control, 44(11), e275-e278. doi: 
10.1016/j.ajic.2016.03.059 
Gaibani, P., Colombo, R., Arghittu, M., Cariani, L., Ambretti, S., Bua, G., . . . Sambri, V. (2014). 
Successful containment and infection control of a Carbapenem-resistant Klebsiella 
pneumoniae outbreak in an Italian hospital. New Microbiol, 37(1), 87-90.  
Gang, Z., & Jie, F. (2016). The intrinsic resistance of bacteria. Yi Chuan, 38(10), 872-880. doi: 
10.16288/j.yczz.16-159 
Gopalakrishnan, R., & Sureshkumar, D. (2010). Changing trends in antimicrobial susceptibility 
and hospital acquired infections over an 8 year period in a tertiary care hospital in relation 
to introduction of an infection control programme. J Assoc Physicians India, 58 Suppl, 25-
31.  
Heudorf, U., Albert-Braun, S., Hunfeld, K. P., Birne, F. U., Schulze, J., Strobel, K., . . . Brandt, C. 
(2016). Multidrug-resistant organisms in refugees: prevalences and impact on infection 
control in hospitals. GMS Hyg Infect Control, 11, Doc16. doi: 10.3205/dgkh000276 
Hsu, L. Y., Apisarnthanarak, A., Khan, E., Suwantarat, N., Ghafur, A., & Tambyah, P. A. (2017). 
Carbapenem-Resistant Acinetobacter baumannii and Enterobacteriaceae in South and 
Southeast Asia. Clin Microbiol Rev, 30(1), 1-22. doi: 10.1128/CMR.00042-16 
Jonathan R. Edwards, M., Kelly D. Peterson, BBA, Mary L. Andrus, BA, RN, CIC, James S. 
Tolson, BS, Joy S. Goulding,, Margaret A. Dudeck, M., Randy B. Mincey, BA, Daniel A. 
Pollock, MD, Teresa C. Horan, MPH, and the NHSN Facilities, & Atlanta, G. (2006). 
National Healthcare Safety Network 
U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 
National Healthcare Safety Network Report, data summary for 2006. AJIC, June(2007), 
290-301.  
 40 
Judd, W. R., Ratliff, P. D., Hickson, R. P., Stephens, D. M., & Kennedy, C. A. (2016). Clinical and 
economic impact of meropenem resistance in Pseudomonas aeruginosa-infected patients. 
Am J Infect Control, 44(11), 1275-1279. doi: 10.1016/j.ajic.2016.04.218 
Kollef, M. H. (2001). Optimizing antibiotic therapy in the intensive care unit setting. Crit Care, 
5(4), 189-195.  
Lalueza, A., Sanz-Trepiana, L., Bermejo, N., Yaiza, B., Morales-Cartagena, A., Espinosa, M., . . . 
Aguado, J. M. (2016). Risk factors for bacteremia in urinary tract infections attended in the 
emergency department. Intern Emerg Med. doi: 10.1007/s11739-016-1576-6 
Lee, B. R., Goldman, J. L., Yu, D., Myers, A. L., Stach, L. M., Hedican, E., . . . Newland, J. G. 
(2016). Clinical Impact of an Antibiotic Stewardship Program at a Children's Hospital. 
Infect Dis Ther. doi: 10.1007/s40121-016-0139-5 
Magiorakos, A. P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., . . . 
Monnet, D. L. (2012). Multidrug-resistant, extensively drug-resistant and pandrug-resistant 
bacteria: an international expert proposal for interim standard definitions for acquired 
resistance. Clin Microbiol Infect, 18(3), 268-281. doi: 10.1111/j.1469-0691.2011.03570.x 
Miller-Keane. (2003). Enterobacteriaceae.  
Nelson, R. E., Schweizer, M. L., Perencevich, E. N., Nelson, S. D., Khader, K., Chiang, H. Y., . . . 
Samore, M. H. (2016). Costs and Mortality Associated With Multidrug-Resistant 
Healthcare-Associated Acinetobacter Infections. Infect Control Hosp Epidemiol, 37(10), 
1212-1218. doi: 10.1017/ice.2016.145 
Papp-Wallace, K. M., Endimiani, A., Taracila, M. A., & Bonomo, R. A. (2011). Carbapenems: 
past, present, and future. Antimicrob Agents Chemother, 55(11), 4943-4960. doi: 
10.1128/AAC.00296-11 
Pragasam, A. K., Vijayakumar, S., Bakthavatchalam, Y. D., Kapil, A., Das, B. K., Ray, P., . . . 
Veeraraghavan, B. (2016). Molecular characterisation of antimicrobial resistance in 
Pseudomonas aeruginosa and Acinetobacter baumannii during 2014 and 2015 collected 
across India. Indian J Med Microbiol, 34(4), 433-441. doi: 10.4103/0255-0857.195376 
Shields, R. K., Clancy, C. J., Gillis, L. M., Kwak, E. J., Silveira, F. P., Massih, R. C., . . . Nguyen, 
M. H. (2012). Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-
Resistant Acinetobacter baumannii Infections among Solid Organ Transplant Recipients. 
PLoS One, 7(12), e52349. doi: 10.1371/journal.pone.0052349PONE-D-12-26408 [pii] 
Shields, R. K., Potoski, B. A., Haidar, G., Hao, B., Doi, Y., Chen, L., . . . Nguyen, M. H. (2016). 
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance 
Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin 
Infect Dis, 63(12), 1615-1618. doi: 10.1093/cid/ciw636 
Stahl, J., Bergmann, H., Gottig, S., Ebersberger, I., & Averhoff, B. (2015). Acinetobacter 
baumannii Virulence Is Mediated by the Concerted Action of Three Phospholipases D. 
PLoS One, 10(9), e0138360. doi: 10.1371/journal.pone.0138360 
Thummeepak, R., Kongthai, P., Leungtongkam, U., & Sitthisak, S. (2016). Distribution of 
virulence genes involved in biofilm formation in multi-drug resistant Acinetobacter 
baumannii clinical isolates. Int Microbiol, 19(2), 121-129. doi: 10.2436/20.1501.01.270 
Tian, L., Tan, R., Chen, Y., Sun, J., Liu, J., Qu, H., & Wang, X. (2016). Epidemiology of 
Klebsiella pneumoniae bloodstream infections in a teaching hospital: factors related to the 
carbapenem resistance and patient mortality. Antimicrob Resist Infect Control, 5, 48. doi: 
10.1186/s13756-016-0145-0 
Tsioutis, C., Kritsotakis, E. I., Karageorgos, S. A., Stratakou, S., Psarologakis, C., Kokkini, S., & 
Gikas, A. (2016). Clinical epidemiology, treatment and prognostic factors of extensively 
 41 
drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill 
patients. Int J Antimicrob Agents, 48(5), 492-497. doi: 10.1016/j.ijantimicag.2016.07.007 
Tun, Z. M., Moorthy, M., Linster, M., Su, Y. C., Coker, R. J., Ooi, E. E., . . . Tam, C. C. (2016). 
Patterns of medication use and factors associated with antibiotic use among adult fever 
patients at Singapore primary care clinics. Antimicrob Resist Infect Control, 5, 47. doi: 
10.1186/s13756-016-0146-z 
Tuon, F. F., Gortz, L. W., & Rocha, J. L. (2012). Risk factors for pan-resistant Pseudomonas 
aeruginosa bacteremia and the adequacy of antibiotic therapy. Braz J Infect Dis, 16(4), 
351-356. doi: 10.1016/j.bjid.2012.06.009 
Tuon, F. F., Graf, M. E., Merlini, A., Rocha, J. L., Stallbaum, S., Arend, L. N., & Pecoit-Filho, R. 
(2016). Risk factors for mortality in patients with ventilator-associated pneumonia caused 
by carbapenem-resistant Enterobacteriaceae. Braz J Infect Dis. doi: 
10.1016/j.bjid.2016.09.008 
van Duin, D., Kaye, K. S., Neuner, E. A., & Bonomo, R. A. (2013). Carbapenem-resistant 
Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis, 
75(2), 115-120. doi: 10.1016/j.diagmicrobio.2012.11.009 
van Duin, D., & Paterson, D. L. (2016). Multidrug-Resistant Bacteria in the Community: Trends 
and Lessons Learned. Infect Dis Clin North Am, 30(2), 377-390. doi: 
10.1016/j.idc.2016.02.004 
Vincenti, S., Quaranta, G., De Meo, C., Bruno, S., Ficarra, M. G., Carovillano, S., . . . Laurenti, P. 
(2014). Non-fermentative gram-negative bacteria in hospital tap water and water used for 
haemodialysis and bronchoscope flushing: prevalence and distribution of antibiotic 
resistant strains. Sci Total Environ, 499, 47-54. doi: 10.1016/j.scitotenv.2014.08.041 
World Health Organization. (2016). DDD: Definition and General Considerations.  
World Health Organization. (2016). Antimicrobial Resistance Fact Sheet. 2016, from 
http://www.who.int/mediacentre/factsheets/antibiotic-resistance/en/ 
Wire, B. (2016). FDA Grants Fast Track Status for Investigational Antibiotic CARBAVANCE® 
(meropenem-vaborbactam). from 
http://www.businesswire.com/news/home/20160411005581/en/ 
Won, S. Y., Munoz-Price, L. S., Lolans, K., Hota, B., Weinstein, R. A., Hayden, M. K., . . . 
Prevention Epicenter, P. (2011). Emergence and rapid regional spread of Klebsiella 
pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis, 53(6), 532-540. 
doi: 10.1093/cid/cir482 
Zilahi, G., Artigas, A., & Martin-Loeches, I. (2016). What's new in multidrug-resistant pathogens 
in the ICU? Ann Intensive Care, 6(1), 96. doi: 10.1186/s13613-016-0199-4 
 
